Cathy Burgess and Natalie Clayton are quoted on the backlogs of onsite facility inspections by the U.S. Food and Drug Administration and how the delays put generic drug applications at risk.
In the News April 9, 2021
Inside Health Policy, Inside Drug Pricing | FDA: Inspection Lag Puts Generic Drug Exclusivity at Risk
Phone: +1 202 239 3648
Phone: +1 212 210 9573
Related News & Insights
In the News April 16, 2021Inside Health Policy, Inside Drug Pricing | FDA Lays Out Detailed Plan for Conducting Remote Facility InspectionsCathy Burgess comments on how the U.S. Food and Drug Administration is likely to use remote evaluations to resolve as many issues as possible before returning to onsite inspections of facilities.
In the News January 5, 2021Inside Health Policy | FDA Inspection Plans Unclear as EUAs Move toward Full ApprovalsCathy Burgess is quoted on how the Food and Drug Administration might conduct remote inspections of drug manufacturing facilities amid COVID-19.
Health Care Week in Review December 13, 2019Alston & Bird Health Care Week in Review, December 13, 2019This past week saw a flurry of legislative action in Washington as both chambers of Congress took up bills dealing with drug pricing and surprise billing. Read more about these proposals and other news below.
Health Care Week in Review August 9, 2019Alston & Bird Health Care Week in Review, August 9, 2019Below is Alston & Bird’s Health Care Week in Review, which provides a synopsis of the latest news in healthcare regulations, notices, and guidance; federal legislation and congressional committee action; reports, studies, and analyses; and other health policy news.
General Publications October 19, 2018Alston & Bird Healthcare Week in Review, October 19, 2018
Alston & Bird’s Week in Review provides a synopsis of the latest news in health care regulations, notices, and guidance; federal legislation and Congressional committee action; reports, studies, and analyses; and other health policy news.